Transcode Therapeutics, Inc. has been the subject of an amended filing with the U.S. Securities and Exchange Commission (SEC) on September 30, 2024. The filing, an Amendment No. 1 to Schedule 13G, indicates that the reporting persons, 3i, LP, 3i Management LLC, and Maier Joshua Tarlow, have ceased to be the beneficial owners of more than five percent of the outstanding common stock of Transcode Therapeutics. This amendment serves as an exit filing for the reporting persons, effectively updating their beneficial ownership information and amending previous disclosures. The reporting persons have confirmed that their holdings are not for the purpose of changing or influencing the control of the issuer. The principal business address for all reporting persons is listed as 2 Wooster Street, 2nd Floor, New York, NY 10013.

Transcode Therapeutics, Inc. has been the subject of an amended filing with the U.S. Securities and Exchange Commission (SEC) on September 30, 2024. The filing, an Amendment No. 1 to Schedule 13G, indicates that the reporting persons, 3i, LP, 3i Management LLC, and Maier Joshua Tarlow, have ceased to be the beneficial owners of more than five percent of the outstanding common stock of Transcode Therapeutics. This amendment serves as an exit filing for the reporting persons, effectively updating their beneficial ownership information and amending previous disclosures. The reporting persons have confirmed that their holdings are not for the purpose of changing or influencing the control of the issuer. The principal business address for all reporting persons is listed as 2 Wooster Street, 2nd Floor, New York, NY 10013.